HCA Healthcare Q1 2026: Shares Fall 9% After EBITDA Miss

The move: a rare, sharp drop after earnings

HCA Healthcare Inc. (NYSE: HCA) saw a steep sell-off after reporting first-quarter 2026 results, with the stock down about 8% to 9% in Friday trading in multiple reports cited alongside the release. The decline stood out because HCA shares have not been very volatile, with commentary noting only two moves greater than 5% over the last year. That context made the post-earnings reaction notable even though some metrics were broadly in line with expectations.

The market’s focus shifted to two themes repeated across the coverage: softer-than-usual seasonal patient volumes and profitability that came in slightly below what analysts were looking for. Even though HCA reaffirmed full-year 2026 guidance, investors appeared to interpret the unchanged outlook as cautious at a time when positioning may have expected a raise.

Q1 2026 results: small beat on revenue, in-line EPS

HCA reported Q1 2026 revenue of $19.11 billion (USD 19.11 billion), modestly above the $19.09 billion consensus referenced in the text. Revenue also rose 4.3% from $18.32 billion (USD 18.32 billion) a year earlier. Adjusted earnings were reported at $1.15 per share, essentially in line with consensus around $1.14.

Despite the headline stability in revenue and earnings per share, the reaction in the stock suggested investors were more sensitive to underlying utilization trends and operating profitability. Reports described mixed same-facility volume trends, which added to uncertainty around near-term growth assumptions.

The key miss: adjusted EBITDA below expectations

One metric repeatedly cited as the trigger was adjusted EBITDA. HCA reported adjusted EBITDA of $1.8 billion (USD 3.80 billion), slightly below the $1.85 billion (USD 3.85 billion) estimate mentioned. The miss was small in absolute terms, but it came at a time when the market appeared to want clean beats across the board.

Coverage also noted that operating margin showed “significant year-over-year improvement,” but that was not enough to counter the disappointment around EBITDA. In an earnings-driven tape, even a narrow shortfall in a key profitability measure can dominate the narrative.

Softer respiratory season and winter storm hit volumes

Management commentary highlighted an operational issue that investors latched onto: the company did not see a typical seasonal lift in volumes. Respiratory-related admissions and respiratory-related emergency room visits were described as materially lower year over year. In addition, a January winter storm affected patient volumes in certain markets.

Several summaries tied the day’s decline to these utilization dynamics, including references to lower respiratory-related admissions and storm-related disruption. The concern was less about a single quarter and more about what weaker seasonal demand might imply for the remainder of the year if trends persist.

Guidance reaffirmed, but the market wanted more

HCA reaffirmed its previously issued 2026 guidance ranges, including an expectation of 2% to 3% volume growth for the remainder of the year. However, multiple notes argued that reaffirming, rather than raising, guidance can read as conservative when investors were positioned for upward revisions after a quarter that was not a clear miss on revenue or EPS.

The guidance discussion also referenced public policy developments and potential impacts tied to health insurance exchange reforms and the expiration of enhanced premium tax credits. Those factors were cited as part of the assumptions embedded in the outlook.

Conference disclosures: potential headwinds flagged

Separately, the text included conference-related commentary stating management flagged a $100 million to $100 million (USD 0.60 to 0.90 billion) headwind in 2026 tied to changes in Health Insurance Exchange (HIX) volume. It also cited an expected decline in state supplemental payments of $150 million to $150 million (USD 0.25 to 0.45 billion) year over year. Combined, those were described as a potential revenue drag of over $1 billion.

These disclosures were presented as contributing to a market repricing for a more challenging margin environment, even as the company’s broader execution was described as strong in other respects.

Capital returns: buybacks and dividends did not offset concerns

The coverage referenced ongoing capital returns, including share repurchases during the quarter and a declared quarterly dividend. It also cited an announcement of a $10 billion share repurchase program and an increased quarterly dividend in earlier reporting.

A separate note highlighted HCA’s ex-dividend date tied to a $1.78 per share quarterly cash dividend, payable on March 31 to stockholders of record as of March 17. While ex-dividend adjustments can affect daily moves, the text argued that the magnitude of the decline indicated fundamentals, not the dividend, drove the selling.

Valuation debate and shifting sentiment

Several parts of the text pointed to valuation as an overhang. One item cited “near fair value” concerns and a downgrade to “hold” due to valuation and execution risks, including labor, Medicaid, and competition. Another cited a GuruFocus GF Value of $131.18 versus a quoted market price of $174.03 at the time of that note.

Macro commentary was mixed. One note said cooler CPI prints could support risk assets broadly, but added that it was a background tailwind rather than company-specific.

Stock context: drawdown from highs and year-to-date performance

HCA was described as down 7.9% since the beginning of the year and trading at $133.12, about 20.5% below its 52-week high of $145.13 from March 2026. Another datapoint in the supplied text showed a prior close of $146.58 on 10/24/2025, with extended trading at $147.98.

The combination of a sharp one-day decline, mixed volume trends, and a valuation debate helped explain why the market reaction was negative even after a modest revenue beat.

Key numbers at a glance

What investors will watch next

After a volume-driven reset, attention is likely to stay on same-facility utilization trends, particularly whether seasonal patterns normalize after a softer respiratory season and weather disruption. Investors will also track how HCA’s results reflect policy-sensitive areas referenced in guidance assumptions, including health insurance exchange dynamics and Medicaid conversions.

For now, the core takeaway from the supplied reports is clear: the quarter was not defined by a revenue miss, but by softer utilization, a slight EBITDA shortfall, and an unchanged full-year outlook that did not clear a higher bar set by expectations.